Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting

/PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea and Cambridge that is advancing novel drugs for...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Orlando ,Florida ,United States ,Seongnam ,Kyonggi Do ,South Korea ,China ,Republic Of Korea ,American ,Jimmy Jin ,Bridge Biotherapeutics Inc ,Drug Administration ,Biotherapeutics Inc ,American Association For Cancer Research ,American Association ,Cancer Research ,Investigational New Drug Application ,Epidermal Growth ,Factor Receptor ,Tyrosine Kinase Inhibitor ,With Broad Spectrum Activity ,Molecular Therapeutics ,Tyrosine Kinase ,Phosphatase Inhibitors ,Bridge Biotherapeutics ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,